BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...Dorzagliatin sinogliatin. It began a collaboration with Chiesi Farmaceutici S.p.A....
BioCentury | Dec 10, 2020
Management Tracks

Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird

...Plus: management moves at Phagelux, Chiesi, Kanova and Oyster Point By Danielle Golovin, Staff Writer David Ricks has...
...Zwinski is transitioning to general manager and CEO of Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A....
...effective Jan. 1. Zwinski was SVP of sales and head of the cardiovascular business unit at Chiesi.Kanova...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...this year for $21 billion.Arix and Sofinnova Ventures co-led VelosBio’s series A round, investing alongside Pappas, Chiesi...
BioCentury | Sep 18, 2020
Product Development

Moderna trial recruiting faster than protocol anticipated

...metabolic disorders. On Tuesday, it partnered with Chiesi Farmaceutici S.p.A....
BioCentury | Sep 17, 2020
Deals

Ahead of R&D day, Moderna unveils two rare disease deals

...By  Karen Tkach Tuzman, Associate Editor Moderna’s deals with Vertex and Chiesi Group highlight the company’s...
...Inc. (NASDAQ:VRTX), this time focused on editing the CFTR gene, and initiated a collaboration with Chiesi Farmaceutici S.p.A....
...received $20 million in upfront cash and was eligible for $275 million in total milestones.From Chiesi...
BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

...schedule in about 90 days.Priority Review for Fabry, hypercholesterolemia therapiesProtalix BioTherapeutics Inc. (Tel Aviv:PLX; NYSE-A:PLX) and partner Chiesi Farmaceutici S.p.A....
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

...Ltd. (Tokyo:4502; NYSE:TAK) market Glassia, an IV formulation of AAT, to treat AAT deficiency. Kamada, Chiesi Farmaceutici S.p.A....
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Existing investors joining them were Arrowmark Partners, Berkeley Catalyst Fund, BVF Partners, Pappas Capital & Chiesi...
BioCentury | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

...of marketed hemostasis, cardiovascular and infectious disease assets in separate transactions with Mallinckrodt plc (NYSE:MNK), Chiesi Farmaceutici S.p.A....
BioCentury | Aug 7, 2019
Financial News

Glycomine looks toward clinic with Novo-led $33M round

...Kasei Pharma Corp. and Mission Bay Capital also participated, as did existing investors Sanderling and Chiesi...
...NASDAQ:BMRN) and Raptor Pharmaceutical Corp. co-founder Chris Starr. Glycomine raised $12 million from Sanderling and Chiesi...
Items per page:
1 - 10 of 217
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...Dorzagliatin sinogliatin. It began a collaboration with Chiesi Farmaceutici S.p.A....
BioCentury | Dec 10, 2020
Management Tracks

Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird

...Plus: management moves at Phagelux, Chiesi, Kanova and Oyster Point By Danielle Golovin, Staff Writer David Ricks has...
...Zwinski is transitioning to general manager and CEO of Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A....
...effective Jan. 1. Zwinski was SVP of sales and head of the cardiovascular business unit at Chiesi.Kanova...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...this year for $21 billion.Arix and Sofinnova Ventures co-led VelosBio’s series A round, investing alongside Pappas, Chiesi...
BioCentury | Sep 18, 2020
Product Development

Moderna trial recruiting faster than protocol anticipated

...metabolic disorders. On Tuesday, it partnered with Chiesi Farmaceutici S.p.A....
BioCentury | Sep 17, 2020
Deals

Ahead of R&D day, Moderna unveils two rare disease deals

...By  Karen Tkach Tuzman, Associate Editor Moderna’s deals with Vertex and Chiesi Group highlight the company’s...
...Inc. (NASDAQ:VRTX), this time focused on editing the CFTR gene, and initiated a collaboration with Chiesi Farmaceutici S.p.A....
...received $20 million in upfront cash and was eligible for $275 million in total milestones.From Chiesi...
BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

...schedule in about 90 days.Priority Review for Fabry, hypercholesterolemia therapiesProtalix BioTherapeutics Inc. (Tel Aviv:PLX; NYSE-A:PLX) and partner Chiesi Farmaceutici S.p.A....
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

...Ltd. (Tokyo:4502; NYSE:TAK) market Glassia, an IV formulation of AAT, to treat AAT deficiency. Kamada, Chiesi Farmaceutici S.p.A....
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Existing investors joining them were Arrowmark Partners, Berkeley Catalyst Fund, BVF Partners, Pappas Capital & Chiesi...
BioCentury | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

...of marketed hemostasis, cardiovascular and infectious disease assets in separate transactions with Mallinckrodt plc (NYSE:MNK), Chiesi Farmaceutici S.p.A....
BioCentury | Aug 7, 2019
Financial News

Glycomine looks toward clinic with Novo-led $33M round

...Kasei Pharma Corp. and Mission Bay Capital also participated, as did existing investors Sanderling and Chiesi...
...NASDAQ:BMRN) and Raptor Pharmaceutical Corp. co-founder Chris Starr. Glycomine raised $12 million from Sanderling and Chiesi...
Items per page:
1 - 10 of 217